Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of ($0.65), $0.16 worse than the analyst estimate of ($0.49). Revenue for the quarter came in at $2.81 million versus the consensus estimate of $2.73 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.